Investment firms ARCH Venture Partners and 8VC led a $750m Series B round in RESILIENCE, a biopharmaceutical company, with participation from GV and NEA. "Our aim with RESILIENCE is to improve manufacturing of breakthrough medicines so that they are more accessible to patients and to foster scientific innovation that makes new modalities of medicine possible," Rahul Singhvi, RESILIENCE Co-Founder and CEO.